Quantcast
Home > Quotes > KURA
KURA

Kura Oncology, Inc. Common Stock (KURA) Quote & Summary Data

$13.4
*  
0.20
1.47%
Get KURA Alerts
*Delayed - data as of Dec. 7, 2018  -  Find a broker to begin trading KURA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    KURA Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
26.5
Today's High / Low
$ 13.87 / $ 13.11
Share Volume
219,381
50 Day Avg. Daily Volume
270,387
Previous Close
$ 13.60
52 Week High / Low
$ 24.025 / $ 10.20
Market Cap
509,695,157
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.68
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.73

Intraday Chart

Shares Traded

Share Volume:
219,381
50 Day Avg. Daily Volume:
270,387

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.68

Trading Range

The current last sale of $13.40 is 31.37% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 13.87 $ 24.025
 Low: $ 13.11 $ 10.20

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule product candidates that target cancer signaling pathways, and we intend to pair them with molecular or cellular diagnostics to identify those patients most likely to respond to treatment. We intend to advance our product candidates through a combination of internal development and strategic partnerships and maintain significant development and commercial rights. Our lead product candidate, tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. Tipifarnib was previously studied in more than 5,000 cancer patients and demonstrated compelling and durable anti-cancer activity in certain patients with a manageable side effect profile. We are currently evaluating tipifarnib in multiple solid tumor and hematologic indications.  ... More ...  


Risk Grade

Where does KURA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 13.68
Open Date:
Dec. 7, 2018
Close Price:
$ 13.40
Close Date:
Dec. 7, 2018

Consensus Recommendation

Analyst Info